BPTH · Bio-Path Holdings, Inc.
$0.13
-0.08 (-38.10%)
At close · Feb 19
Going-concern doubt
— flagged May 20, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company’s available cash and cash equivalents of $0.1 million at March 31, 2026 will not be sufficient to fund liquidity and capital expenditure requirements for the next 12 months from the date of issuance of these consolidated financial statements. Therefore, substantial doubt exists about the Company’s ability to continue as a going concern.”View the 10-Q filed May 20, 2026
Market Cap
$1.51M
Shares
50.30M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$0
-100%
FY2018
Net Income
-$9.89M
+38.5%
FY2024
Operating Margin
-24232.43%
+40959.9pp
FY2017
Diluted EPS
-$4.12
+87.7%
FY2024
Operating Cash Flow
-$10.58M
+8.3%
FY2024
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | $0 | $37K | $13K | $0 | $0 | $0 | $0 | $0 | — | |
| — | $7.3M | $11.61M | $9.17M | $5.91M | $6.58M | $4.59M | $4.6M | $5.48M | $5.47M | $3.02M | $1.63M | $1.52M | $1.13M | — | — | |
| — | $4.7M | $4.24M | $4.74M | $4.53M | $4.33M | $4.11M | $3.38M | $3.52M | $3.01M | $2.47M | $2.72M | $1.63M | $986.1K | $1.22M | $1.13M | |
| — | — | — | — | — | — | $0 | $161K | — | — | — | $1.25M | $1.09M | $928.23K | $791.46K | — | |
| — | $11.99M | $15.84M | $13.9M | $10.44M | $10.91M | $8.69M | $8.59M | $9M | $8.49M | $5.49M | $4.54M | $3.27M | $2.58M | $2.37M | $2.33M | |
| — | -$11.99M | -$15.84M | -$13.9M | -$10.44M | -$10.91M | -$8.69M | -$8.59M | -$8.97M | -$8.48M | -$5.49M | -$4.54M | -$3.27M | -$2.58M | -$2.37M | -$2.33M | |
| — | — | — | — | — | — | — | — | -24232.43% | -65192.31% | — | — | — | — | — | — | |
| — | $14K | $36K | $33K | $3000 | $26K | $94K | $7000 | $9000 | $12K | $18K | $23K | $4037 | $779 | $2907 | $1302 | |
| — | $2.1M | -$235K | $33K | $3000 | $26K | $94K | $7000 | $1.94M | $1.73M | $18K | $23K | $3227 | $142 | $2271 | $244.93K | |
| — | -$9.89M | -$16.08M | -$13.87M | -$10.44M | -$10.88M | -$8.6M | -$8.58M | -$7.02M | -$6.75M | -$5.47M | -$4.56M | -$3.27M | -$2.58M | -$2.36M | -$2.08M | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| — | -$9.89M | -$16.08M | -$13.87M | -$10.44M | -$10.88M | -$8.6M | -$8.58M | -$7.02M | -$6.75M | -$5.47M | -$4.52M | -$3.27M | -$2.58M | -$2.36M | -$2.08M | |
| — | — | — | — | — | — | — | — | -18981.08% | -51923.08% | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | -$8.58M | -$8.06M | -$6.75M | — | — | — | — | — | — | |
| USD/shares | $0.97 | -$4.12 | -$33.63 | -$38.12 | -$31.00 | -$56.60 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$4.12 | -$33.63 | -$38.12 | -$31.00 | -$56.60 | — | — | — | — | — | — | — | — | — | — |
| shares | — | 2.4M | 478K | 364K | 336.25K | 192.35K | 132.85K | 29.85K | 25.2K | 463.5K | 4.49M | 4.46M | 3.57M | 2.97M | 2.69M | — |
| shares | — | 2.4M | 478K | 364K | 336.25K | 192.35K | 132.85K | 29.85K | 25.2K | 463.5K | 4.49M | 4.46M | 3.57M | 2.97M | 2.69M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.12×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 108 similar-size Biotechnology companies (of 537 listed).